Literature DB >> 27496950

Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.

Karen M McCammon1, Satya P Panda1, Chuanwu Xia2, Jung-Ja P Kim2, Daniela Moutinho3, Michel Kranendonk3, Richard J Auchus4, Eileen M Lafer1, Debashis Ghosh5, Pavel Martasek6, Rekha Kar1, Bettie Sue Masters7, Linda J Roman8.   

Abstract

Human NADPH-cytochrome P450 oxidoreductase (POR) gene mutations are associated with severe skeletal deformities and disordered steroidogenesis. The human POR mutation A287P presents with disordered sexual development and skeletal malformations. Difficult recombinant expression and purification of this POR mutant suggested that the protein was less stable than WT. The activities of cytochrome P450 17A1, 19A1, and 21A2, critical in steroidogenesis, were similar using our purified, full-length, unmodified A287P or WT POR, as were those of several xenobiotic-metabolizing cytochromes P450, indicating that the A287P protein is functionally competent in vitro, despite its functionally deficient phenotypic behavior in vivo Differential scanning calorimetry and limited trypsinolysis studies revealed a relatively unstable A287P compared with WT protein, leading to the hypothesis that the syndrome observed in vivo results from altered POR protein stability. The crystal structures of the soluble domains of WT and A287P reveal only subtle differences between them, but these differences are consistent with the differential scanning calorimetry results as well as the differential susceptibility of A287P and WT observed with trypsinolysis. The relative in vivo stabilities of WT and A287P proteins were also examined in an osteoblast cell line by treatment with cycloheximide, a protein synthesis inhibitor, showing that the level of A287P protein post-inhibition is lower than WT and suggesting that A287P may be degraded at a higher rate. Current studies demonstrate that, unlike previously described mutations, A287P causes POR deficiency disorder due to conformational instability leading to proteolytic susceptibility in vivo, rather than through an inherent flavin-binding defect.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  POR deficiency; cytochrome P450; cytochrome P450 oxidoreductase; diflavin oxidoreductase; flavoprotein; membrane protein; protein crystallization; protein stability; reductase

Mesh:

Substances:

Year:  2016        PMID: 27496950      PMCID: PMC5034044          DOI: 10.1074/jbc.M116.716019

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Folding screening assayed by proteolysis: application to various cystine deletion mutants of vascular endothelial growth factor.

Authors:  C Heiring; Y A Muller
Journal:  Protein Eng       Date:  2001-03

2.  Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase.

Authors:  Colin J Henderson; Diana M E Otto; Dianne Carrie; Mark A Magnuson; Aileen W McLaren; Ian Rosewell; C Roland Wolf
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

3.  Stopped-flow kinetic studies of flavin reduction in human cytochrome P450 reductase and its component domains.

Authors:  A Gutierrez; L Y Lian; C R Wolf; N S Scrutton; G C Roberts
Journal:  Biochemistry       Date:  2001-02-20       Impact factor: 3.162

4.  Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase.

Authors:  Anna L Shen; Kathleen A O'Leary; Charles B Kasper
Journal:  J Biol Chem       Date:  2001-12-12       Impact factor: 5.157

5.  Compound heterozygous mutations of cytochrome P450 oxidoreductase gene (POR) in two patients with Antley-Bixler syndrome.

Authors:  Masanori Adachi; Katsuhiko Tachibana; Yumi Asakura; Toshiyuki Yamamoto; Keiichi Hanaki; Akira Oka
Journal:  Am J Med Genet A       Date:  2004-08-01       Impact factor: 2.802

6.  Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase.

Authors:  Jun Gu; Yan Weng; Qing-Yu Zhang; Huadong Cui; Melissa Behr; Lin Wu; Weizhu Yang; Li Zhang; Xinxin Ding
Journal:  J Biol Chem       Date:  2003-04-15       Impact factor: 5.157

7.  Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.

Authors:  Christa E Flück; Toshihro Tajima; Amit V Pandey; Wiebke Arlt; Kouji Okuhara; Charles F Verge; Ethylin Wang Jabs; Berenice B Mendonça; Kenji Fujieda; Walter L Miller
Journal:  Nat Genet       Date:  2004-02-01       Impact factor: 38.330

8.  Suppression of human cytochrome P450 aromatase activity by monoclonal and recombinant antibody fragments and identification of a stable antigenic complex.

Authors:  Puloma Lala; Tadayoshi Higashiyama; Mary Erman; Jennifer Griswold; Traci Wagner; Yoshio Osawa; Debashis Ghosh
Journal:  J Steroid Biochem Mol Biol       Date:  2004-03       Impact factor: 4.292

9.  Riboflavin therapy. Biochemical heterogeneity in two adult lipid storage myopathies.

Authors:  L Vergani; M Barile; C Angelini; A B Burlina; L Nijtmans; M P Freda; C Brizio; E Zerbetto; F Dabbeni-Sala
Journal:  Brain       Date:  1999-12       Impact factor: 13.501

10.  Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study.

Authors:  Wiebke Arlt; Elizabeth A Walker; Nicole Draper; Hannah E Ivison; Jon P Ride; Fabian Hammer; Susan M Chalder; Maria Borucka-Mankiewicz; Berthold P Hauffa; Ewa M Malunowicz; Paul M Stewart; Cedric H L Shackleton
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

View more
  7 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

2.  Lipid-exchange in nanodiscs discloses membrane boundaries of cytochrome-P450 reductase.

Authors:  Carlo Barnaba; Thirupathi Ravula; Ilce G Medina-Meza; Sang-Choul Im; G M Anantharamaiah; Lucy Waskell; Ayyalusamy Ramamoorthy
Journal:  Chem Commun (Camb)       Date:  2018-06-14       Impact factor: 6.222

3.  The Hinge Segment of Human NADPH-Cytochrome P450 Reductase in Conformational Switching: The Critical Role of Ionic Strength.

Authors:  Diana Campelo; Thomas Lautier; Philippe Urban; Francisco Esteves; Sophie Bozonnet; Gilles Truan; Michel Kranendonk
Journal:  Front Pharmacol       Date:  2017-10-30       Impact factor: 5.810

4.  The Role of the FMN-Domain of Human Cytochrome P450 Oxidoreductase in Its Promiscuous Interactions With Structurally Diverse Redox Partners.

Authors:  Francisco Esteves; Diana Campelo; Bruno Costa Gomes; Philippe Urban; Sophie Bozonnet; Thomas Lautier; José Rueff; Gilles Truan; Michel Kranendonk
Journal:  Front Pharmacol       Date:  2020-03-18       Impact factor: 5.810

5.  Loss of Protein Stability and Function Caused by P228L Variation in NADPH-Cytochrome P450 Reductase Linked to Lower Testosterone Levels.

Authors:  Maria Natalia Rojas Velazquez; Mathias Noebauer; Amit V Pandey
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

6.  Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population.

Authors:  Shabbir Ahmed; Jie Zhou; Zhan Zhou; Shu-Qing Chen
Journal:  Genes (Basel)       Date:  2018-10-22       Impact factor: 4.096

7.  Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase.

Authors:  Shaheena Parween; Maria Natalia Rojas Velazquez; Sameer S Udhane; Norio Kagawa; Amit V Pandey
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.